ReviewMolecular diversity2026
Drug repurposing: a promising drug discovery strategy for the treatment of emerging epidemic infectious disease.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.Therapeutic innovation & regulatory science · 2026Review
- Artificial intelligence in respiratory medicine: From diagnosis to treatment and future directions.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Guanidines: Privileged Scaffolds Against Neglected Tropical Diseases: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Epidemic refers to a disease when the occurrence level exceeds expected standards (generating an epidemic phenomenon), in which infectious diseases pose a major challenge to global health. The concept of epidemiology arises with infectious diseases, which can infect many people within a certain period and lead to a pandemic. Especially in the face of sudden epidemics, time is of the essence. In such urgent scenarios, the time required for traditional drug discovery is often prohibitive, given its inherently long timelines, high costs, and frequent failures. Drug repurposing strategies, mainly divided into experimental and computational approaches,which involves identifying new therapeutic applications for already approved pharmaceuticals, have gained substantial attention as a time-efficient and cost-effective alternative. In light of this, the present review provides a comprehensive overview of the various approaches to drug repurposing for the treatment of emerging epidemic infectious diseases, the majority of which are sudden epidemics caused by viruses. In addition, we discuss the challenges faced by repurposing and propose innovative approaches to address these challenges to better achieve the successful translation of drug repurposing into clinical applications and maximize the therapeutic value of drugs.
Indexed as
Identifiers
40608229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.